Eli Lilly and Company (NYSE:LLY) Stock Price Up 1.8% - Still a Buy?

Key Points

• LLY rose 1.8% on Monday, trading near $966 after touching $995, as investors continued to favor the stock’s strong momentum and growth profile.
• Fundamentals remain very strong: the company recently beat quarterly EPS and revenue expectations by a wide margin, with revenue up 55.5% year over year and analysts forecasting continued growth.
• Sentiment is mostly bullish, with Barclays lifting its price target to $1,400 and maintaining an Overweight rating, though a regulatory hiccup in India forced Lilly to pause an obesity awareness campaign.

Eli Lilly and Company (NYSE:LLY - Get Free Report) rose 1.8% during mid-day trading on Monday . The stock traded as high as $995.00 and last traded at $965.8490. Approximately 3,102,072 shares were traded during trading, a decline of 3% from the average daily volume of 3,212,879 shares. The stock had previously closed at $948.45.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Barclays raised its price target on Eli Lilly to $1,400 from $1,350 and kept an Overweight rating, signaling continued confidence in the company’s long-term growth outlook. Barclays Sees Reinforced Long-Term Growth Narrative for Eli Lilly and Company (LLY)
• Positive Sentiment: Investor sentiment is also being lifted by reports that Lilly’s revenue growth remains exceptionally strong, with the company’s CFO discussing a 56% year-over-year revenue beat. Eli Lilly CFO Lucas Montrace Explains What Drove 56% Year-over-Year Revenue Beat
• Positive Sentiment: Lilly’s obesity and diabetes franchise continues to be viewed favorably, with commentary noting that Mounjaro has overtaken Merck’s Keytruda as the best-selling drug, reinforcing the strength of its GLP-1 portfolio. Eli Lilly's Mounjaro surpasses Merck's Keytruda as best-selling drug
• Neutral Sentiment: Several market articles highlighted Lilly as a top momentum and growth stock, adding to the bullish narrative but offering little new company-specific information. Why Eli Lilly (LLY) is a Top Momentum Stock for the Long-Term
• Neutral Sentiment: Lilly was also mentioned in a proposed acquisition of Centessa Pharmaceuticals, which could be mildly strategic over time but is not yet a direct earnings driver. Centessa Pharmaceuticals Investor Alert
• Negative Sentiment: Eli Lilly paused an obesity awareness campaign in India after the country’s drugs regulator warned it may violate rules against indirect prescription-drug advertising, creating a near-term regulatory overhang. Exclusive: Lilly halts India obesity awareness campaign after regulatory scrutiny, seeks rules clarity

Analyst Upgrades and Downgrades

LLY has been the topic of several research analyst reports. Wall Street Zen upgraded shares of Eli Lilly and Company from a "buy" rating to a "strong-buy" rating in a research report on Saturday, May 2nd. UBS Group reiterated a "buy" rating on shares of Eli Lilly and Company in a research report on Wednesday, March 18th. Cantor Fitzgerald boosted their price target on shares of Eli Lilly and Company from $1,205.00 to $1,230.00 and gave the company an "overweight" rating in a research report on Friday, May 1st. CICC Research boosted their price target on shares of Eli Lilly and Company from $1,060.00 to $1,107.00 and gave the company a "neutral" rating in a research report on Wednesday, February 11th. Finally, Barclays boosted their price target on shares of Eli Lilly and Company from $1,350.00 to $1,400.00 and gave the company an "overweight" rating in a research report on Monday, May 4th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $1,218.33.

Eli Lilly and Company Trading Up 1.8%

The firm has a market cap of $909.58 billion, a PE ratio of 34.31, a PEG ratio of 1.03 and a beta of 0.48. The company has a quick ratio of 1.10, a current ratio of 1.50 and a debt-to-equity ratio of 1.26. The stock's fifty day simple moving average is $943.90 and its two-hundred day simple moving average is $990.90.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its quarterly earnings data on Thursday, April 30th. The company reported $8.55 earnings per share for the quarter, topping analysts' consensus estimates of $6.97 by $1.58. The business had revenue of $19.80 billion for the quarter, compared to analysts' expectations of $17.82 billion. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The business's revenue was up 55.5% compared to the same quarter last year. During the same quarter in the prior year, the company earned $3.34 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. On average, sell-side analysts forecast that Eli Lilly and Company will post 35.8 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, June 10th. Shareholders of record on Friday, May 15th will be issued a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a yield of 0.7%. The ex-dividend date is Friday, May 15th. Eli Lilly and Company's dividend payout ratio is 24.58%.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the company. 10Elms LLP lifted its stake in shares of Eli Lilly and Company by 33.3% in the third quarter. 10Elms LLP now owns 40 shares of the company's stock worth $31,000 after buying an additional 10 shares in the last quarter. M.E. Allison & CO. Inc. lifted its stake in shares of Eli Lilly and Company by 0.7% in the fourth quarter. M.E. Allison & CO. Inc. now owns 1,477 shares of the company's stock worth $1,587,000 after buying an additional 10 shares in the last quarter. Tanager Wealth Management LLP lifted its stake in shares of Eli Lilly and Company by 2.6% in the fourth quarter. Tanager Wealth Management LLP now owns 395 shares of the company's stock worth $424,000 after buying an additional 10 shares in the last quarter. Morey & Quinn Wealth Partners LLC lifted its stake in shares of Eli Lilly and Company by 1.5% in the fourth quarter. Morey & Quinn Wealth Partners LLC now owns 661 shares of the company's stock worth $710,000 after buying an additional 10 shares in the last quarter. Finally, Wealthspan Partners LLC lifted its stake in shares of Eli Lilly and Company by 0.5% in the fourth quarter. Wealthspan Partners LLC now owns 2,110 shares of the company's stock worth $2,268,000 after buying an additional 10 shares in the last quarter. Institutional investors own 82.53% of the company's stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.